(Q38253835)

PubMed publication ID

1 September 2017

2 references

14 September 2020

Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

1 reference

14 September 2020

1 reference

14 September 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

Cheryl L Stevens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

Jayalakshmi Sridhar

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

language of work or name

English

0 references

publication date

23 September 2014

2 references

PubMed publication ID

1 September 2017

14 September 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

14 September 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

page(s)

15196-15212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

Creative Commons Attribution

13 May 2020

1 reference

14 September 2020

0 references

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Progress in breast cancer: overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Metastasis dormancy in estrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

p95HER2 and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Targeting receptor tyrosine kinases in HER2-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Recent advances in drug design of epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Targeting HER receptors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Beyond trastuzumab: new treatment options for HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Mechanism of action of anti-HER2 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for hu

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Protein kinase inhibitors: insights into drug design from structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Mechanism of activation and inhibition of the HER4/ErbB4 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Irreversible protein kinase inhibitors: balancing the benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Selectively nonselective kinase inhibition: striking the right balance

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Discovery of selective irreversible inhibitors for EGFR-T790M.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190915196

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

12 December 2020

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

12 December 2020

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors

1 reference

12 December 2020

The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo

1 reference

12 December 2020

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human

1 reference

12 December 2020

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

1 reference

12 December 2020

P95 HER2 fragments and breast cancer outcome

1 reference

12 December 2020

Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer

1 reference

12 December 2020

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

1 reference

12 December 2020

Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

12 December 2020

10.3390/MOLECULES190915196

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json

13 May 2020

PubMed publication ID

25251190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6270702&resulttype=core&format=json